at Nasdaq.com (Jan 16, 2015)
Thoratec (THOR -3.8%) trades down after UBS cut the shares to Neutral from Buy on valuation. The firm says the stock may be played out over the near term, as peer competitor Heartware's (HTWR +1%) pending launch of HVAD is expected to cut into its heart therapy market share.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 2, 2015)
at Nasdaq.com (Dec 15, 2014)
at Zacks.com (Dec 3, 2014)
at Nasdaq.com (Nov 21, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs